ArticleMedicine2026
Vasoactive intestinal peptide associated 8-gene signature with prognostic and immune associations in melanoma.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vasoactive intestinal peptide (VIP) plays a multifaceted role in cancer biology, yet its prognostic and immunological implications in melanoma remain underexplored. This study aimed to construct a VIP-related gene signature for risk stratification and to explore its potential associations with the tumor immune microenvironment and drug sensitivity in melanoma. RNA-sequencing data and clinical information were obtained from TCGA-SKCM (n = 477, training set) and GSE65904 (n = 209, validation set). A VIP-related prognostic signature (VIPsig) was developed using stepwise Cox regression and Gradient Boosting Machine algorithms. Patients were stratified into high- and low-risk groups based on the median risk score. Somatic mutations, immune infiltration, drug sensitivity, and functional enrichment were further analyzed. A nomogram integrating clinical factors was developed and validated. Single-cell RNA-seq data (GSE115978) were reanalyzed to characterize cellular expression patterns. A preliminary pan-cancer analysis indicated potential dysregulation of VIP pathway genes. In melanoma, we identified an 8-gene signature (CD28, CD80, CD86, CTLA4, FAS, IFNG, IL10, and IL12A) associated with survival. In the training set, high-risk patients exhibited significantly worse overall survival (OS) compared to low-risk patients (HR = 2.96, 95% CI: 2.24-3.92, P < .001). This was validated in the GSE65904 cohort (HR = 1.87, 95% CI: 1.26-2.77, P = .002). The VIPsig demonstrated discriminative ability with 1-, 3-, and 5-year AUCs of 0.760 (95% CI: 0.675-0.845, P < .001), 0.749 (95% CI: 0.692-0.807, P < .001), and 0.770 (95% CI: 0.717-0.823, P < .001) in the training set, respectively. Functionally, the signature was significantly associated with immune cell infiltration and immune checkpoint expression. In silico drug sensitivity analysis suggested potential associations with estimated IC50 values for several agents, though these findings require experimental validation. A nomogram integrating VIPsig with clinicopathological factors showed improved net benefit in decision curve analysis. The VIP-based signature demonstrates robust prognostic value for melanoma survival and reflects the tumor immune microenvironment status. Exploratory analyses suggest potential associations with in silico drug sensitivity estimates; however, its utility for treatment response prediction remains unvalidated and warrants further investigation in prospective melanoma cohorts treated with immune checkpoint inhibitors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.